Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BRAIN Biotech AGHAM:BNN 69 ROC (Joel Greenblatt) % is -40.51% as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 69/100 and a GF Value™ of €2.52 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,605 Chemicals companies, BRAIN Biotech AG ranks worse than 93.77% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. BRAIN Biotech AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -40.51%.
The historical rank and industry rank for BRAIN Biotech AG's ROC (Joel Greenblatt) % or its related term are showing as below:
HAM:BNN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -135.65 Med: -36.03 Max: -14.11
Current: -35.11
During the past 11 years, BRAIN Biotech AG's highest ROC (Joel Greenblatt) % was -14.11%. The lowest was -135.65%. And the median was -36.03%.
HAM:BNN's ROC (Joel Greenblatt) % is ranked worse than 93.77% of 1605
companies
in the Chemicals industry
Industry Median: 9.47
vs HAM:BNN: -35.11
BRAIN Biotech AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -0.40% per year.
BRAIN Biotech AG (HAM:BNN) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
BRAIN Biotech AG ROC (Joel Greenblatt) % Related Terms
BRAIN Biotech AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: ROC (Joel Greenblatt) % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG ROC (Joel Greenblatt) % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's ROC (Joel Greenblatt) % falls into.
BRAIN Biotech AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -40.51% mean?
BRAIN Biotech AG (HAM:BNN) has a ROC (Joel Greenblatt) % of -40.51% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #1505 out of 1605 companies in the Chemicals industry, placing it in the top 93.8%.
Is BRAIN Biotech AG's ROC (Joel Greenblatt) % too high?
BRAIN Biotech AG's current ROC (Joel Greenblatt) % is -40.51%. Based on the distribution chart, BRAIN Biotech AG ranks #1505 out of 1605 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's ROC (Joel Greenblatt) % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1505 out of 1605 companies for ROC (Joel Greenblatt) %. This places BRAIN Biotech AG in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 9.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Chemicals company?
The median ROC (Joel Greenblatt) % among Chemicals companies is 9.47, based on 1,605 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median ROC (Joel Greenblatt) % is 9.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current ROC (Joel Greenblatt) % is -40.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.77 — trading 9.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is -40.51%. BRAIN Biotech AG's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current ROC (Joel Greenblatt) % is -40.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.77 is trading 9.9% above its estimated GF Value™ of €2.52.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
ROC (Joel Greenblatt) %: -40.51%
GF Value™: €2.52 vs. price of €2.77 (9.9% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
69GF Score
Get the complete analysis for HAM:BNN
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
